Hamza Hanif

Hamza Hanif

Auto-generated profile, based on publicly available information

Hamza Hanif

Department of Surgery, University of New Mexico School of Medicine, Albuquerque, NM 87131

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2021 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
IGIshan Garg
Ishan Garg
HHHamza Hanif
Hamza Hanif
NJNismat Javed
Nismat Javed
RARamsha Abbas
Ramsha Abbas
SMSamir Mirza
Samir Mirza
Abu Baker SheikhAbu Baker Sheikh
Abu Baker Sheikh
The coronavirus 2019 (COVID-19) pandemic has disproportionately impacted lesbian, gay, bisexual, transgender, queer (LGBTQ+) people. Despite developing safe and effective COVID-19 vaccines, LGBTQ+ communities still faces challenges due to inequitable access and vaccine hesitancy. Vaccine hesitancy is a delay in the acceptance or refusal of vaccines despite the availability of vaccination services. Various studies have explored and tried to address factors influencing vaccine hesitancy. However, the LGBTQ+ population remains under- and misrepresented in many of these studies. According to the few studies that have focused on the LGBTQ+ population, several factors influencing vaccine hesitancy have been identified, with the most common factors in studies being concern about vaccine safety, vaccine efficacy, and history of bad experiences with healthcare providers. In order to rebuild the confidence of LGBTQ+ people in vaccines, governments, healthcare policymakers, and healthcare providers need to start by acknowledging, and then resolving, these disparities; building trust; dismantling systemic suppression and discrimination; and prioritizing the inclusion of LGBTQ+ people in research studies and public health policies.

17 February 2022 in Journal of Community Hospital Internal Medicine Perspectives
Verified
Journal Article
Open access
PDF file
Abu Baker SheikhAbu Baker Sheikh
Abu Baker Sheikh
SMSamir Mirza
Samir Mirza
RARamsha Abbas
Ramsha Abbas
NJNismat Javed
Nismat Javed
ANAnthony Nguyen
Anthony Nguyen
AFAsif Farooq
Asif Farooq
Introduction: Acute esophageal necrosis (AEN) is an uncommon but fatal cause of upper gastrointestinal bleeding. The complex pathophysiology of the disorder provides multiple points for intervention. Therefore, it is important to discuss the many multifaceted aspects of the disease. Methods: A scoping review was performed using PubMed, Google Scholar, and ClinicalTrials.gov. We reviewed literature from 1990 to 2021. The keywords used were ‘acute esophageal necrosis’, ‘upper GI bleed’, ‘pathogenesis’, ‘EGD’, ‘prognosis’. Results and conclusions: The review summarized findings of 46 studies. AEN usually targets older males who have underlying cardiovascular disease. The middle part of the esophagus is commonly involved. The pathogenesis of AEN depends on conditions that increase risk of mucosal damage such as ischemia, lack of mucosal protection and excessive gastric reflux. Some medications are also responsible for the disease. Esophagogastroduodenoscopy is usually the gold standard for diagnosis. Findings suggestive of AEN include darkened, sharply demarcated circumferential areas. Supportive measures, including bowel rest, fluid supplementation and proton pump inhibitors are the cornerstone of therapy. A high index of suspicion should be maintained in patients with chronic health problems presenting with signs and symptoms of upper gastrointestinal bleeding because AEN can carry an unfavorable prognosis in these patients.

4 July 2022 in Journal of Community Hospital Internal Medicine Perspectives
Verified
Journal Article
Open access
PDF file
ANAnthony Nguyen
Anthony Nguyen
SMSamir Mirza
Samir Mirza
NJNismat Javed
Nismat Javed
HHHamza Hanif
Hamza Hanif
MRMoon Ryu
Moon Ryu
Abu Baker SheikhAbu Baker Sheikh
Abu Baker Sheikh
Introduction: Acute liver failure is a cause of major mortality in the United States. Although the liver possesses regenerative capabilities, liver transplantation is the mainstay of treating acute liver failure. This modality is associated with many financial and logistic challenges. In this regard, Extracorporeal Liver Support (ECLS) might help in reducing mortality as well as bridge a patient to liver transplant. In some cases, the sequelae of liver failure such as hepatic encephalopathy and multi-organ failure can be postponed long enough for the native liver to self-recover function. With this rationale, we sought to describe the mechanism of various ECLS modalities, provide an overview of the current evidence regarding its use and to highlight future advancements that could overcome hindrances in its use. Methods: A scoping review was performed using PubMed and other databases from 1990 to 2020 with the keywords: ‘extracorporeal liver support’, ‘acute liver failure’, ‘acute on chronic liver failure’, ‘albumin dialysis’, ‘artificial’ and ‘bioartificial’. Results and conclusions: ECLS has shown significant improvements in bilirubin and urea levels. Various forms of ECLS might also reduce mortality due to liver failure. However, many complications, such as hypotension, anemia, bleeding issues, sepsis, can be anticipated. There are a few barriers to mainstream use of ECLS, such as specific design requirements and high cost that reduce the overall utility of this modality in a small group of liver transplant candidates. Furthermore, a multidisciplinary team approach is required to supervise ECLS, a luxury only available at major academic hospitals. Some advancements for overcoming these barriers include investigation of new scaffolding systems. In order to expand the usage of ECLS, clinical trials focusing on a comparison of different modalities of ECLS with renal replacement therapy in patients with liver failure should be promoted.

1 October 2021 in Geriatrics
Verified
Journal Article
Open access
PDF file
Abu Baker SheikhAbu Baker Sheikh
Abu Baker Sheikh
NJNismat Javed
Nismat Javed
KLKatarina Leyba
Katarina Leyba
AKAli Hamza Khair
Ali Hamza Khair
ZIZAINAB IJAZ
ZAINAB IJAZ
Rahul ShekharRahul Shekhar
Rahul Shekhar
Delirium leading to agitation is a common issue in elderly people and patients with underlying neurocognitive impairment. Despite use of medications to treat agitation, polypharmacy is a major concern and might lead to multiple side effects in this patient population. Therefore, it is imperative to investigate non-pharmacological methods that can provide solutions to the problem. The objective of this review was to evaluate the impact of pet-assisted therapy on elderly patients, with a major focus on agitation and delirium. For the purposes of this study, a scoping review was performed using PubMed, Google Scholar, and ClinicalTrials. We reviewed literature from 1980 to 2021. Out of the 31 studies reviewed, 14 commented on agitation with respect to pet-assisted interventions. Of these, eight studies (57%) reported a statistically significant reduction in agitation and/or delirium in patients who were exposed to pet therapy. Pet-assisted therapy can improve the standardized care in hospital-based settings for patients with neurocognitive impairment because of better companionship, reduced agitation and mood disorders, and better stability of hemodynamic status. These interventions can pave the way for better patient and hospital satisfaction.

24 May 2023 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
HHHamza Hanif
Hamza Hanif
RCRoss Clark
Ross Clark
SMSarah Moore
Sarah Moore
NMNathan T. Morrell
Nathan T. Morrell
JMJohn Marek
John Marek
SGSundeep Guliani
Sundeep Guliani

29 February 2024 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
KLKatarina Leyba
Katarina Leyba
HHHamza Hanif
Hamza Hanif
AMAlexandra C. Millhuff
Alexandra C. Millhuff
MQMohammed A. Quazi
Mohammed A. Quazi
ASAmir H. Sohail
Amir H. Sohail
MRMuhammad A. Rana
Muhammad A. Rana